{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:25Z","timestamp":1782107365371,"version":"3.54.5"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lecanemab and donanemab are anti-amyloid-\u03b2 (A\u03b2) monoclonal antibodies recently approved for the treatment of Alzheimer\u2019s disease (AD). Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and compared in spontaneous reporting systems. This study aimed to systematically compare adverse event signals associated with these two drugs using the FDA Adverse Event Reporting System database, with sex-stratified and sensitivity analyses performed to support the main findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports up to the fourth quarter of 2025 were retrospectively analyzed. Reports in which lecanemab or donanemab was recorded as the primary suspect drug were included. AEs were classified by system organ classes (SOCs) and preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA). Signal detection was performed using four algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Sex-stratified analysis, sensitivity analysis after excluding reports involving concomitant medications, and time-to-onset (TTO) analysis based on the Weibull shape parameter model were also conducted. False discovery rate (FDR) correction was applied to analyses involving multiple P values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,640 AE reports were identified, including 2,602 for lecanemab and 1,038 for donanemab. Nervous system disorders was the most frequently reported SOC and the only SOC meeting the positivity criteria across all four algorithms for both drugs. At the PT level, the frequently reported events for both drugs were mainly concentrated in amyloid-related imaging abnormality (ARIA)-related events, including ARIA with oedema\/effusion (ARIA-E) and ARIA with microhaemorrhages\/haemosiderin deposition (ARIA-H), headache, and infusion-related reactions. The strongest disproportionality reporting signals were mainly observed for ARIA-related preferred terms and cerebral microhaemorrhage. In separate FAERS-based disproportionality analyses, lecanemab showed stronger disproportionality reporting signals for ARIA-H, whereas donanemab showed stronger disproportionality reporting signals for ARIA-E. In addition, drug-specific PT signal distributions differed between the two agents. Several potential novel PT signals were also identified. Sex-stratified analysis suggested differences in the distribution of certain PT signals between female and male reports. Sensitivity analysis supported the stability of most core signals. The median TTO was 46 days for lecanemab and 31 days for donanemab, and Weibull analysis suggested different temporal patterns of AE occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using four signal detection algorithms, this study compared real-world adverse event reporting profiles associated with lecanemab and donanemab. The two drugs showed both shared and distinct adverse event reporting profiles, particularly in ARIA subtype-related disproportionality signals, drug-specific PT signals, potential novel reporting signals, sex-stratified reporting patterns, and TTO characteristics. These findings provide pharmacovigilance evidence for targeted safety monitoring and hypothesis generation, but should not be interpreted as causal associations or true incidence estimates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1868789","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:36Z","timestamp":1782106776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiuping","family":"Feng","sequence":"first","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangqing","family":"Bi","sequence":"additional","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiong","family":"Shi","sequence":"additional","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Chang","sequence":"additional","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Zhuang","sequence":"additional","affiliation":[{"name":"The Seventh Clinical College of Guangzhou University of Chinese Medicine","place":["Shenzhen, Guangdong, China"]},{"name":"Shenzhen Bao\u2019an Chinese Medicine Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3390\/jpm15090437","article-title":"Anti-amyloid monoclonal antibodies for alzheimer's disease: evidence, ARIA risk, and precision patient selection","volume":"15","author":"Alkhalifa","year":"2025","journal-title":"J. Pers. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","article-title":"Alzheimer's disease","volume":"377","author":"Ballard","year":"2011","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3946320231209839","DOI":"10.1177\/03946320231209839","article-title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for alzheimer's disease: a systematic review","volume":"37","author":"Chowdhury","year":"2023","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"231536","DOI":"10.1098\/rsos.231536","article-title":"A qualitative analysis of an A\u03b2-monomer model with inflammation processes for alzheimer's disease","volume":"11","author":"Ciuperca","year":"2024","journal-title":"R. Soc. Open Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early alzheimer's disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5407","DOI":"10.1002\/alz.13128","article-title":"APOE \u03b54's impact on response to amyloid therapies in early symptomatic alzheimer's disease: analyses from multiple clinical trials","volume":"19","author":"Evans","year":"2023","journal-title":"Alzheimers Dement."},{"key":"B11","unstructured":"FDA converts novel alzheimer's disease treatment to traditional approval\n          \n          \n          2023"},{"key":"B12","unstructured":"FDA approves treatment for adults with alzheimer's disease\n          \n          \n          2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and alzheimer disease\u2014one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"key":"B18","doi-asserted-by":"publisher","first-page":"102348","DOI":"10.1016\/j.arr.2024.102348","article-title":"Donanemab, another anti-alzheimer's drug with risk and uncertain benefit","volume":"99","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1436405","DOI":"10.3389\/fphar.2024.1436405","article-title":"Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Jiang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"103949","DOI":"10.1016\/j.mcn.2024.103949","article-title":"Lecanemab demonstrates highly selective binding to A\u03b2 protofibrils isolated from alzheimer's disease brains","volume":"130","author":"Johannesson","year":"2024","journal-title":"Mol. Cell. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","article-title":"Donanemab: first approval","volume":"84","author":"Kang","year":"2024","journal-title":"Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40261-023-01331-1","article-title":"Lecanemab: more questions than answers","volume":"44","author":"Kaur","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1593989","DOI":"10.3389\/fphar.2025.1593989","article-title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","volume":"16","author":"Kong","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"30495334251376614","DOI":"10.1177\/30495334251376614","article-title":"An update of the treatment landscape for alzheimer's disease: from symptomatic treatments to the emergence of amyloid-targeting therapies","volume":"11","author":"Kovacik","year":"2025","journal-title":"Sage Open Aging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol","volume":"13","author":"Kubota","year":"2004","journal-title":"Drug Saf."},{"key":"B26","first-page":"791","article-title":"Signal mining and analysis of adverse events for donanemab based on FAERS database","volume":"32","author":"Li","year":"2026","journal-title":"J. Pediatr. Pharm."},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jad.2025.01.022","article-title":"Characteristics of adverse events and clinical risks of lecanemab based on FAERS data","volume":"374","author":"Li","year":"2025","journal-title":"J. Affect. Disord."},{"key":"B28","article-title":"2023 world alzheimer's disease report: reducing dementia risk: never too early, never too late","author":"Long","year":"2023","journal-title":"Alzheimer's Dis. Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13195-026-02022-7","article-title":"Amyloid-related imaging abnormalities (ARIA) in alzheimer's disease: from pathophysiology to individualized risk assessment","volume":"18","author":"Merkel","year":"2026","journal-title":"Alzheimers Res. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13195-025-01912-6","article-title":"Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data","volume":"17","author":"Noguchi-Shinohara","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e53995","DOI":"10.7554\/eLife.53995","article-title":"Sleep is bi-directionally modified by amyloid beta oligomers","volume":"9","author":"\u00d6zcan","year":"2020","journal-title":"eLife"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13954","DOI":"10.3390\/ijms232213954","article-title":"Alzheimer's disease: treatment strategies and their limitations","volume":"23","author":"Passeri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1101\/2023.11.20.23298794","article-title":"N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for alzheimer's disease: a systematic review and comprehensive meta-analysis","author":"Qiu","year":"2023"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1111\/bcp.15673","article-title":"A post-marketing pharmacovigilance study of avapritinib: adverse event data mining and analysis based on the United States food and drug administration adverse event reporting system database","volume":"90","author":"Rong","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13195-019-0539-3","article-title":"Participant and study partner prediction and identification of cognitive impairment in preclinical alzheimer's disease: study partner vs. participant accuracy","volume":"11","author":"Ryan","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical alzheimer's disease: implications for prevention trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B40","unstructured":"KISUNLA (Donanemab-azbt) injection, for intravenous use: initial U.S. approval 2024\n          \n          \n          2025"},{"key":"B41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.tjpad.2025.100094","article-title":"Lecanemab for early alzheimer's disease: appropriate use recommendations from the French Federation of memory clinics","volume":"12","author":"Villain","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"o3010","DOI":"10.1136\/bmj.o3010","article-title":"Lecanemab for alzheimer's disease","volume":"379","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"853096","DOI":"10.3389\/fcimb.2022.853096","article-title":"Neuroinflammation, sleep, and circadian rhythms","volume":"12","author":"Zielinski","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1868789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:46Z","timestamp":1782106786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1868789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":46,"alternative-id":["10.3389\/fphar.2026.1868789"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1868789","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1868789"}}